ELISA News and Research

RSS
Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

30 Mar 2022
Engineering rotavirus-based vaccine vectors expressing SARS-CoV-2 spike epitopes

Engineering rotavirus-based vaccine vectors expressing SARS-CoV-2 spike epitopes

30 Mar 2022
A ferritin nanoparticle candidate vaccine for COVID

A ferritin nanoparticle candidate vaccine for COVID

30 Mar 2022
Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

29 Mar 2022
Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

28 Mar 2022
Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

28 Mar 2022
SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

27 Mar 2022
UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

24 Mar 2022
Researchers investigate Galectin-9 as a new treatment target for COVID-19

Researchers investigate Galectin-9 as a new treatment target for COVID-19

23 Mar 2022
Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

23 Mar 2022
Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

23 Mar 2022
The effect of SARS-CoV-2 on the expression of CD48 in the lungs and in the peripheral blood of COVID-19 patients

The effect of SARS-CoV-2 on the expression of CD48 in the lungs and in the peripheral blood of COVID-19 patients

22 Mar 2022
Study evaluates interactions between SARS-CoV-2 proteins and viral and host RNA

Study evaluates interactions between SARS-CoV-2 proteins and viral and host RNA

22 Mar 2022
Waning antibody responses in SARS-CoV-2-infected or vaccinated population

Waning antibody responses in SARS-CoV-2-infected or vaccinated population

22 Mar 2022
Association between seropositivity and comorbidities after COVID-19 vaccination

Association between seropositivity and comorbidities after COVID-19 vaccination

22 Mar 2022
A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

21 Mar 2022
Glycogen synthase kinase-3 inhibitors found to attenuate COVID-19-associated cytokine storm

Glycogen synthase kinase-3 inhibitors found to attenuate COVID-19-associated cytokine storm

21 Mar 2022
Study aimed to identify the direct pathway that associates integrins with vascular dysregulation during SARS-CoV-2 infection

Study aimed to identify the direct pathway that associates integrins with vascular dysregulation during SARS-CoV-2 infection

21 Mar 2022
Response to COVID-19 boosters in seronegative multiple sclerosis patients

Response to COVID-19 boosters in seronegative multiple sclerosis patients

20 Mar 2022
Study evaluates COVID-19 vaccination with recombinant accessory protein-deficient SARS-CoV-2

Study evaluates COVID-19 vaccination with recombinant accessory protein-deficient SARS-CoV-2

18 Mar 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback